US Stock Market Movement: Rapport plunges on October 21 due to safety concerns, limited efficacy, and profit-taking.

Rapport October 21: Interpretation of the Sharp Decline

Keywords: Safety concerns, limited efficacy margin, profit-taking

On October 20, 2026, the company announced that the RAP-219 Phase II trial for bipolar mania had achieved both primary and secondary endpoints. However, the agitation incidence rate in the drug group was higher than in the placebo group, 16.7% compared to 9.4%, and the discontinuation rate due to adverse events was also higher, 3.2% compared to 0.8%. Analysts also pointed out that the improvement in symptom scores of the drug compared to placebo was 3.1 points, which was below the expectations of some investors. After a sharp rise in pre-market trading, the stock price subsequently fell, and profit-taking may have further increased volatility.

(Disclaimer: This content is generated by AI technology using publicly available information and is for reference only. It does not constitute investment advice.)